An updated meta-analysis on the association of X-ray repair cross complementing group 1 codon 399 polymorphism with hepatocellular carcinoma risk.

Ya-Dong Wang,Wen-Long Zhai,Hai-Yu Wang,Xiang-Qun Xia

doi:10.7314/apjcp.2014.15.11.4443

Ya-Dong Wang, Wen-Long Zhai + Show 2 more

Open Access

https://doi.org/10.7314/apjcp.2014.15.11.4443

Copy DOI

Abstract

A number of studies have reported the association of X-ray repair cross-complementing group 1 (XRCC1) Arg399Gln polymorphism with susceptibility to hepatocellular carcinoma (HCC). However, the results were inconsistent and inconclusive. The aim of this study was to comprehensively explore the association of XRCC1 Arg399Gln variant with HCC risk. Systematic searches of PubMed, Elsevier, Science Direct, CNKI and Chinese Biomedical Literature Database were performed. Pooled odds ratio (OR) with 95% confidence intervals (CI) was calculated to estimate the strength of association. Overall, we observed an increased HCC risk among subjects carrying XRCC1 codon 399 Gln/Gln, Arg/Gln and Gln/ Gln+Arg/Gln genotypes (OR=1.20, 95%CI: 1.05-1.38, OR=1.16, 95%CI: 1.05-1.28, and OR=1.14, 95%CI: 1.04-1.24, respectively) based on 20 studies including 3374 cases and 4633 controls. In subgroup analysis, we observed an increased risk of XRCC1 codon 399 Gln/Gln, Arg/Gln and Gln/Gln+Arg/Gln polymorphisms for HCC in hospital-based study (OR=1.25, 95%CI: 1.03-1.51, OR=1.21, 95%CI: 1.07-1.36 and OR=1.18, 95%CI: 1.06-1.31, respectively) and in Asian population (OR=1.19, 95%CI: 1.03-1.38, OR=1.17, 95%CI: 1.04-1.30 and OR=1.14, 95%CI: 1.04-1.25, respectively). Limiting the analysis to the studies with controls in agreement with Hardy-Weinberg equilibrium (HWE), we observed an increased HCC risk among Gln/Gln, Arg/Gln and Gln/ Gln+Arg/Gln genotype carriers (OR=1.17, 95%CI: 1.05-1.29, OR=1.12, 95%CI: 1.00-1.25 and OR=1.11, 95%CI: 1.02-1.21, respectively). This updated meta-analysis results suggest that XRCC1 Arg399Gln variants may contribute to HCC risk. Well-designed studies with larger sample size were required to further verify our findings.

Highlights

Liver cancer in men is the fifth most frequently diagnosed cancer worldwide and the second most frequent cause of cancer death
Literature and methods We carried out a systematic search in Pubmed/Medline, Elsevier, Science direct, Chinese National Knowledge Infrastructure (CNKI) and Chinese Biomedical Literature Database, covering all papers published before December 1, 2013 with a combination of the following terms: “hepatocellular cancer” or “hepatocellular carcinoma” or “liver cancer” or “liver tumor”, “polymorphism” and “X-ray repair cross-complementing group 1 (XRCC1)”
Data from studies were included in our meta-analysis only if the study met the following criteria: (1) The papers should include hepatocellular carcinoma (HCC) risk and polymorphism of XRCC1 codon 399; (2) Only the case-control studies or cohort studies were considered; (3) The paper must offer the sample size, odds ratio (OR) with 95% confidence intervals (CI) or the information that can help infer the results; (4) When more than one article was identified for the same study population, we included the publication including more information

Summary

Introduction

Liver cancer in men is the fifth most frequently diagnosed cancer worldwide and the second most frequent cause of cancer death. Results: Overall, we observed an increased HCC risk among subjects carrying XRCC1 codon 399 Gln/Gln, Arg/Gln and Gln/ Gln+Arg/Gln genotypes (OR=1.20, 95%CI: 1.05-1.38, OR=1.16, 95%CI: 1.05-1.28, and OR=1.14, 95%CI: 1.04-1.24, respectively) based on 20 studies including 3374 cases and 4633 controls. We observed an increased risk of XRCC1 codon 399 Gln/Gln, Arg/Gln and Gln/Gln+Arg/Gln polymorphisms for HCC in hospital-based study (OR=1.25, 95%CI: 1.03-1.51, OR=1.21, 95%CI: 1.07-1.36 and OR=1.18, 95%CI: 1.06-1.31, respectively) and in Asian population (OR=1.19, 95%CI: 1.03-1.38, OR=1.17, 95%CI: 1.04-1.30 and OR=1.14, 95%CI: 1.04-1.25, respectively). Limiting the analysis to the studies with controls in agreement with Hardy-Weinberg equilibrium (HWE), we observed an increased HCC risk among Gln/Gln, Arg/Gln and Gln/ Gln+Arg/Gln genotype carriers (OR=1.17, 95%CI: 1.05-1.29, OR=1.12, 95%CI: 1.00-1.25 and OR=1.11, 95%CI: 1.02-1.21, respectively). Well-designed studies with larger sample size were required to further verify our findings

Objectives

Methods

Results

Conclusion